Ontology highlight
ABSTRACT: Background and aims
Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for patients with severe, treatment-refractory Crohn's disease [CD]. The evidence base for AHSCT for CD is limited, with one randomised trial [ASTIC] suggesting benefit. The aim of this study was to evaluate safety and efficacy for patients undergoing AHSCT for CD in Europe, outside the ASTIC trial.Methods
We identified 99 patients in the European Society for Blood and Marrow Transplantation [EBMT] registry, who were eligible for inclusion. Transplant and clinical outcomes were obtained for 82 patients from 19 centres in seven countries.Results
Median patient age was 30 years [range 20-65]. Patients had failed or been intolerant to a median of six lines of drug th
SUBMITTER: Brierley CK
PROVIDER: S-EPMC6113702 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature